Topics

FDA Grants Priority Review to Tazemetostat for Relapsed/Refractory Follicular Lymphoma

19:00 EST 13 Feb 2020 | Cancer Networks

The submission was primarily based on updated phase II efficacy and safety data for tazemetostat for patients with relapsed or refractory follicular lymphoma who have received at least 2 prior lines of systemic therapy.

Original Article: FDA Grants Priority Review to Tazemetostat for Relapsed/Refractory Follicular Lymphoma

NEXT ARTICLE

More From BioPortfolio on "FDA Grants Priority Review to Tazemetostat for Relapsed/Refractory Follicular Lymphoma"

Quick Search

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...